| Code | CSB-RA023601MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Tomaralimab, designed to specifically target Toll-like receptor 2 (TLR2), a critical pattern recognition receptor in the innate immune system. TLR2 recognizes a diverse array of pathogen-associated molecular patterns, including lipoproteins, peptidoglycans, and lipoteichoic acids from bacteria, fungi, and viruses. Upon ligand binding, TLR2 initiates downstream signaling cascades through MyD88-dependent pathways, leading to the activation of NF-κB and the production of pro-inflammatory cytokines. Dysregulated TLR2 signaling has been implicated in various pathological conditions, including sepsis, atherosclerosis, autoimmune disorders, inflammatory diseases, and cancer progression.
Tomaralimab represents an investigational therapeutic antibody that modulates TLR2 activity and has been explored in clinical settings for its potential to regulate inflammatory responses. This biosimilar provides researchers with a valuable tool for investigating TLR2-mediated immune mechanisms, studying innate immunity pathways, examining host-pathogen interactions, and exploring therapeutic interventions in inflammation-driven diseases. It enables detailed characterization of TLR2 function in cellular and molecular immunology research.
There are currently no reviews for this product.